Skip to main content
Lady Gaga, Actual Nurtec ODT Patient

The only migraine medication approved to treat and prevent all in one1,2

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 8/21/23.

Lady Gaga Actual Nurtec ODT patient.

More than 126,000 providers have written over 4.8 million prescriptions for Nurtec ODT

The flexibility to help meet your patients’ needs1

Only Nurtec ODT treats and prevents all in one1,2

Well tolerated for acute and preventive treatment1

Dedicated access, savings, and support resources through Nurtec® OneSource

Requesting samples or other tools is one short form away

Per IQVIA XPO report, accessed 8/25/23. Rankings included new prescriptions and renewals.

More than 296 million individuals have access to Nurtec ODT across all channels*

With coverage for 96% of commercially insured lives*

Find specific formulary coverage in your area:

Auto-locate

OR

*Per Managed Markets Insights & Technology LLC as of 12/04/23.

The Migraine Q&A

Tell us a bit about yourself and see if you know the answers to 5 questions on patients' migraine experience and Nurtec ODT as a treatment option.

Ellie's migraine story

Ellie
Stress is a trigger for
my migraine attacks.
I know I can count on
Nurtec ODT to help
relieve pain when
a migraine attack strikes in stressful times.

Ellie W.
Actual Nurtec ODT patient.
Individual results may vary.

Patients were invited to share their experiences on Nurtec ODT. All content was accurate at the time of publication.

Greg's migraine story

After years on the
battlefield and multiple concussions, migraine attacks followed me home...Nurtec ODT is the only medication that can treat and prevent migraine attacks.

Greg P.
Actual Nurtec ODT patient.
Individual results may vary.

Patients were invited to share their experiences on Nurtec ODT. All content was accurate at the time of publication.

References: 1. Nurtec ODT. Package insert. Pfizer Inc. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7.